Business and Finance

Watch for Washington tax policy reform to affect 2017 business

Shorter elapsed time in recent years shows encouraging improvement

Only 20 new molecular entities passed muster this year, less than half of 2015’s total

New consumer-education campaign led by Alliance for Safe Online Pharmacies

A preamble for a next round of legislating drug pricing?

Action is expected to meet FTC objections to the merged chains announced in 2015

Back to square one in addressing high-cost-drug spending

Connecticut leads 20 states suing an alleged ring led by Heritage Pharma

First branded-product discount program from Blink Health

Higher productivity and more complexity; but slow takeup of traceability requirements

Growth rates will moderate in the US and world

Bills passes House with broad bipartisan support; Senate approval likely

A counterargument to the belief that out-of-pocket expenses originate with insurers or PBMs

Sale comes with multi-year supply agreement

Two Canadian Accucaps facilities join global network of 11 Catalent RP Scherer Softgel locations

Allergan’s big commitment to NJ; U. of Michigan converts pharma facilities to healthcare and education

Upcoming trial could explore the intricacies of ‘alternative fulfillment’ via specialty pharmacies

An Amazon-like model for creating an open market for wholesalers to reach customers

Will employer benefit plans lose their enthusiasm for PBMs?

Revenues and earnings were up for the year; stock jumps 8.8% in the day

McKesson disappoints on Q2 earnings call; stock drops 23%. Update: Cardinal reports more revenue, less profit

Price growth is less than branded growth, but higher than inflation

Company may have erroneously been operating under a generic classification

New company is to be known as QuintilesIMS

Drug dispensing, point of care testing and diagnostics are beneficiaries

Drug Channel’s analysis of Inc. 5000 shows some eye-popping growth

CIS by Deloitte seeks to provide a comprehensive service for revenue management

Mylan CEO sticks to authorized-generic strategy for price relief

Roche could overtake Novartis as the No. 1 global firm by then, says Evaluate Pharma